The Food and Drug Administration on Friday afternoon announced it is denying the use of MDMA-assisted therapy for the treatment of post-traumatic stress disorder, a major setback for the 13 million people looking for a new treatment for the mental health disorder.

The public health agency was expected to release the decision on the approval of the ecstasy-based drug the week of Aug. 12.

Recommended Stories

Fast-track post-traumatic stress treatments. Our veterans can’t wait

FDA approves Eli Lilly Alzheimer’s drug

FDA declines to approve leucovorin for autism despite Trump team hype